Cogstate Ltd (ASX:CGS) provides digital cognitive assessment technology used in Clinical Trials and healthcare settings. The company supports pharmaceutical and biotechnology research by providing tools that measure cognitive function across areas including neurological and other therapeutic studies.

The company’s FY2026 results highlighted higher revenue, improved profitability and growth in contracted work. Future performance will depend on the conversion of contracted opportunities, clinical trial activity and continued Demand for digital assessment solutions.

Recent Development

Cogstate released its FY2026 results in August 2026 for the year ended 30 June 2026.

The company reported Revenue of US$60.9 million, representing growth compared with the previous year. EBITDA increased to US$18.3 million, with the company reporting an EBITDA Margin of 30 per cent for the full year.

Profit before tax increased during FY2026, while net profit after tax also recorded growth compared with the prior corresponding period.

Cogstate announced a fully Franked Dividend of A$0.04 per share, representing an increase from the previous distribution.

Company Profile

Founded in 1999, Cogstate develops digital cognitive assessment technology for clinical research and healthcare applications.

The company’s clinical trials Business supports pharmaceutical and biotechnology companies conducting research programs, particularly in areas where cognitive measurement is an important study outcome.

Cogstate’s technology is used across multiple therapeutic areas, including neurology, rare diseases and other healthcare research fields.

Contract Pipeline

Cogstate reported growth in new sales contracts during FY2026, reflecting increased demand for its clinical trial technology solutions.

Total contracted revenue across future periods increased, providing visibility over future revenue recognition. A portion of this contracted revenue is expected to be recognised during FY2027.

The company continues to focus on converting contracted opportunities into recognised revenue as clinical trials progress.

Outlook

Cogstate expects continued revenue growth in FY2027, with performance dependent on the timing and scale of new contracts and clinical trial activity.

The company has also outlined plans to increase technology investment, including development activities related to artificial intelligence capabilities.

Future financial updates will provide further visibility on contract conversion, operating margins and Investment requirements.

Key Considerations

Cogstate operates within the pharmaceutical research and clinical trial sector, where project timelines can be affected by sponsor decisions, trial changes and broader research spending conditions.

Contracted revenue remains dependent on customer programs progressing as planned, while increased investment in technology development may influence future cost levels.

As Cogstate reports financial results in US dollars, currency movements may also affect reported figures for Australian investors.

Key Takeaways

Cogstate entered FY2027 with higher FY2026 revenue, improved profitability and increased clinical trial activity. The company’s upcoming updates will provide further information on contract execution, trial activity and progress across its technology investments.